A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has a histologically confirmed diagnosis of locally advanced unresectable ormetastatic (unresectable Stage III or Stage IV as defined by American JointCommittee on Cancer [AJCC] eighth edition) colorectal adenocarcinoma

• Part 2 only: Has not received systemic anticancer therapy for locally advancedunresectable or metastatic colorectal cancer

• Tumor tissue demonstrates presence of a Kirsten rat sarcoma viral oncogene homologG12C (KRAS G12C) mutation

• Human immunodeficiency virus (HIV)-infected participants must have well controlledHIV on antiretroviral therapy (ART)

• Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible ifthey have received hepatitis B virus (HBV) antiviral therapy and have undetectableHBV viral load

• Participants with history of hepatitis C virus (HCV) infection are eligible if HCVviral load is undetectable

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has active inflammatory bowel disease requiring immunosuppressive medication orprevious clear history of inflammatory bowel disease (eg, Crohn's disease,ulcerative colitis, chronic diarrhea)

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

• Has known dihydropyrimidine dehydrogenase (DPD) deficiency

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease

• Has received prior systemic anticancer therapy including investigational agentswithin 4 weeks before randomization

• Has 1 or more conditions that, in the opinion of the investigator, make theparticipant ineligible for treatment with bevacizumab

• Has known additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• Has known active central nervous system (CNS) metastases and/or carcinomatousmeningitis or leptomeningeal disease

• Has active infection requiring systemic therapy

• Has not adequately recovered from major surgery or have ongoing surgicalcomplications

• Has a history of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease